Studies on the pharmacology of alpha-methyl-3,4-dihydroxyphenylalanine (alpha-methyl-dopa) and alpha-methyl-norepinephrine. I.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002415:Cats; D004558:Electric Stimulation; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D008297:Male; D008750:Methyldopa / Q000494:pharmacology*; D008995:Monoamine Oxidase; D009411:Nerve Endings / Q000187:drug effects; D009469:Neuromuscular Junction / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology; D009541:Nictitating Membrane / Q000187:drug effects*; D009647:Normetanephrine / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000502:physiology; D013564:Sympathetic Nervous System / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects; D014439:Tyramine / Q000494:pharmacology; D014649:Vas Deferens / Q000187:drug effects
D009647:Normetanephrine; D000804:Angiotensin II; D008750:Methyldopa; D009538:Nicotine; D012110:Reserpine; D008995:Monoamine Oxidase; D014439:Tyramine; D010646:Phentolamine